Between all of the gynecological cancers, ovarian cancer, despite medical advances and the development of diagnostic tools such as biomarkers and detection techniques, remains a fatal cancer with high progression. Despite this, there is no effective screening strategy or standard treatment for ovarian cancer. If diagnosed during stage I, ovarian cancer has a 90% 5-year survival rate; however, there is usually a masking of symptoms which leads to an often late-stage diagnosis and correspondingly poor survival rate. Current diagnostic methods are invasive and consist of a pelvic examination, transvaginal ultrasonography, and blood tests to detect cancer antigen 125 (CA125). Unfortunately, surgery is often still required to make a positive diagnosis. Epithelial Ovarian Cancer (EOC) is the most common, whereas, stromal and germ cell tumors are of lower abundance. A Risk of Ovarian Malignancy Algorithm (ROMA) classifies patients as being at low or high risk for malignant disease using both the CA125 and HE4 results and a woman's menopausal status. The ROMA index was calculated according to the levels of HE4 and CA-125. HE4 and CA-125 values were input to the ovarian cancer risk assessment software, followed by automatic calculation of the corresponding ROMA index. The premenopausal calculation formula of the ROMA index was: 12+2.38 × LN (HE4) +0.062 6 × LN (CA-125). The postmenopausal calculation formula of the ROMA index was: 8.09+1.04 × LN (HE4) +0.732 × LN (CA-125). Such diagnostic medical methods and biomarkers include vaginal and pelvic examination, diagnostic imaging, serum CA125, and screening tests or a combination used in medical centers, however, it is necessary to find new biomarkers with long-term stability and high specificity and sensitivity to detect Ovarian Ca in early stages of disease.